Review



easysep human cord blood cd34 positive selection kit iii  (STEMCELL Technologies Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    STEMCELL Technologies Inc easysep human cord blood cd34 positive selection kit iii
    Easysep Human Cord Blood Cd34 Positive Selection Kit Iii, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/easysep+human+cord+blood+cd34+positive+selection+kit/easysep+human+t+cell+isolation+kit/pm40632850-144-6-15
    Average 90 stars, based on 1 article reviews
    easysep human cord blood cd34 positive selection kit iii - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    Selection:

    Article Title: Establishment and Characterization of Humanized Mouse NPC-PDX Model for Testing Immunotherapy.
    Article Snippet: The cord blood was purified by density centrifugation with Lymphoprep (Stemcell Technologies, Vancouver, BC, Canada) and red blood cells (RBC) were lysed by EasySep RBC lysis buffer (Stemcell Technologies). .. Thereafter, human CD34+ HSCs were enriched using EasySep Human Cord Blood CD34 Positive Selection kit (Stemcell Technologies) according to manufacturer’s instructions. ..

    Article Title: Expanding the genetic code of the human hematopoietic system
    Article Snippet: .. Mononuclear cells were separated from cord blood using Ficoll-Paque PLUS (GE Healthcare), and the CD34 + cells were subsequently purified using the EasySep Human Cord Blood CD34 Positive Selection Kit (StemCell Technologies) following manufacturer’s instruction. .. Isolated CD34 + cells were cultured in HSC expansion media (StemSpan SFEM II [StemCell Technologies], supplemented with the following recombinant human cytokines: thrombopoietin, IL6, Flt3 ligand, and stem cell factor [100 ng/mL for all, R&D Systems], and 1 μM SR1 [Selleckchem]) for 5 d before nucleofection.

    Article Title: Establishment and Characterization of Humanized Mouse NPC-PDX Model for Testing Immunotherapy
    Article Snippet: The cord blood was purified by density centrifugation with Lymphoprep (Stemcell Technologies, Vancouver, BC, Canada) and red blood cells (RBC) were lysed by EasySep RBC lysis buffer (Stemcell Technologies). .. Thereafter, human CD34 + HSCs were enriched using EasySep Human Cord Blood CD34 Positive Selection kit (Stemcell Technologies) according to manufacturer’s instructions. .. NSG mice were purchased from The Jackson Laboratory and bred in a specific pathogen-free condition at Biological Resource Centre (BRC) in Agency for Science, Technology and Research (A*STAR), Singapore.

    Article Title: Single-cell RNA sequencing reveals anti-tumor potency of CD56 + NK cells and CD8 + T cells in humanized mice via PD-1 and TIGIT co-targeting
    Article Snippet: Leukocytes were enriched by density centrifugation with Lymphoprep (STEMCELL Technologies, Vancouver, BC, Canada) and red blood cells (RBCs) were lysed using EasySep RBC lysis buffer (STEMCELL Technologies). .. Thereafter, human CD34 + hematopoietic stem cells (HSCs) were isolated using the EasySep human cord blood CD34 positive selection kit (STEMCELL Technologies), according to the manufacturer’s instructions. ..

    Article Title: Expanding the genetic code of the human hematopoietic system.
    Article Snippet: .. Mononuclear cells were separated from cord blood using FicollPaque PLUS (GE Healthcare), and the CD34+ cells were subsequently purified using the EasySep Human Cord Blood CD34 Positive Selection Kit (StemCell Technologies) following manufacturer’s instruction. .. Isolated CD34+ cells were cultured in HSC expansion media (StemSpan SFEM II [StemCell Technologies], supplemented with the following recombinant human cytokines: thrombopoietin, IL6, Flt3 ligand, and stem cell factor [100 ng/mL for all, R&D Systems], and 1 μM SR1 [Selleckchem]) for 5 d before nucleofection.

    Article Title: A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer.
    Article Snippet: Donor human umbilical cord blood was first balanced with equal volume of PBS and then 35ml of balanced blood was added to 15ml of Lymphoprep Density gradient medium (Stem Cell technologies, Cat#7861) to isolate mononuclear cells. .. Human CD34+ hematopoietic stem cells (HSCs) were isolated from processed mononuclear cells using EasySep Human Cord Blood CD34 Positive Selection Kit (Stemcell, Cat#17896). ..

    Article Title: Hexokinase 3 enhances myeloid cell survival via non-glycolytic functions
    Article Snippet: .. Under approved institutional protocol and in accordance with the Declaration of Helsinki, CD34 + cells were isolated using either the EasySep Human Cord Blood CD34 Positive Selection Kit according to the manufacturer’s instructions (STEMCELL Technologies) or the human CD34 MicroBead Ultrapure kit (Miltenyi Biotech) followed by automatic separation on the autoMACS Pro Separator (Miltenyi Biotech). ..

    Article Title: Single-cell RNA sequencing reveals anti-tumor potency of CD56 + NK cells and CD8 + T cells in humanized mice via PD-1 and TIGIT co-targeting.
    Article Snippet: Leukocytes were enriched by density centrifugation with Lymphoprep (STEMCELL Technologies, Vancouver, BC, Canada) and red blood cells (RBCs) were lysed using EasySep RBC lysis buffer (STEMCELL Technologies). .. Thereafter, human CD34+ hematopoietic stem cells (HSCs) were isolated using the EasySep human cord blood CD34 positive selection kit (STEMCELL Technologies), according to the manufacturer’s instructions. ..

    Purification:

    Article Title: Expanding the genetic code of the human hematopoietic system
    Article Snippet: .. Mononuclear cells were separated from cord blood using Ficoll-Paque PLUS (GE Healthcare), and the CD34 + cells were subsequently purified using the EasySep Human Cord Blood CD34 Positive Selection Kit (StemCell Technologies) following manufacturer’s instruction. .. Isolated CD34 + cells were cultured in HSC expansion media (StemSpan SFEM II [StemCell Technologies], supplemented with the following recombinant human cytokines: thrombopoietin, IL6, Flt3 ligand, and stem cell factor [100 ng/mL for all, R&D Systems], and 1 μM SR1 [Selleckchem]) for 5 d before nucleofection.

    Article Title: Expanding the genetic code of the human hematopoietic system.
    Article Snippet: .. Mononuclear cells were separated from cord blood using FicollPaque PLUS (GE Healthcare), and the CD34+ cells were subsequently purified using the EasySep Human Cord Blood CD34 Positive Selection Kit (StemCell Technologies) following manufacturer’s instruction. .. Isolated CD34+ cells were cultured in HSC expansion media (StemSpan SFEM II [StemCell Technologies], supplemented with the following recombinant human cytokines: thrombopoietin, IL6, Flt3 ligand, and stem cell factor [100 ng/mL for all, R&D Systems], and 1 μM SR1 [Selleckchem]) for 5 d before nucleofection.

    Isolation:

    Article Title: Single-cell RNA sequencing reveals anti-tumor potency of CD56 + NK cells and CD8 + T cells in humanized mice via PD-1 and TIGIT co-targeting
    Article Snippet: Leukocytes were enriched by density centrifugation with Lymphoprep (STEMCELL Technologies, Vancouver, BC, Canada) and red blood cells (RBCs) were lysed using EasySep RBC lysis buffer (STEMCELL Technologies). .. Thereafter, human CD34 + hematopoietic stem cells (HSCs) were isolated using the EasySep human cord blood CD34 positive selection kit (STEMCELL Technologies), according to the manufacturer’s instructions. ..

    Article Title: A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer.
    Article Snippet: Donor human umbilical cord blood was first balanced with equal volume of PBS and then 35ml of balanced blood was added to 15ml of Lymphoprep Density gradient medium (Stem Cell technologies, Cat#7861) to isolate mononuclear cells. .. Human CD34+ hematopoietic stem cells (HSCs) were isolated from processed mononuclear cells using EasySep Human Cord Blood CD34 Positive Selection Kit (Stemcell, Cat#17896). ..

    Article Title: Hexokinase 3 enhances myeloid cell survival via non-glycolytic functions
    Article Snippet: .. Under approved institutional protocol and in accordance with the Declaration of Helsinki, CD34 + cells were isolated using either the EasySep Human Cord Blood CD34 Positive Selection Kit according to the manufacturer’s instructions (STEMCELL Technologies) or the human CD34 MicroBead Ultrapure kit (Miltenyi Biotech) followed by automatic separation on the autoMACS Pro Separator (Miltenyi Biotech). ..

    Article Title: Single-cell RNA sequencing reveals anti-tumor potency of CD56 + NK cells and CD8 + T cells in humanized mice via PD-1 and TIGIT co-targeting.
    Article Snippet: Leukocytes were enriched by density centrifugation with Lymphoprep (STEMCELL Technologies, Vancouver, BC, Canada) and red blood cells (RBCs) were lysed using EasySep RBC lysis buffer (STEMCELL Technologies). .. Thereafter, human CD34+ hematopoietic stem cells (HSCs) were isolated using the EasySep human cord blood CD34 positive selection kit (STEMCELL Technologies), according to the manufacturer’s instructions. ..



    Similar Products

    easysep human cord blood cd34 positive selection kit iii  (STEMCELL Technologies Inc)
    90
    STEMCELL Technologies Inc easysep human cord blood cd34 positive selection kit iii
    Easysep Human Cord Blood Cd34 Positive Selection Kit Iii, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/easysep+human+cord+blood+cd34+positive+selection+kit/easysep+human+t+cell+isolation+kit/pm40632850-144-6-15
    Average 90 stars, based on 1 article reviews
    easysep human cord blood cd34 positive selection kit iii - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    easysep human cord blood cd34 positive selection kit ii  (STEMCELL Technologies Inc)
    90
    STEMCELL Technologies Inc easysep human cord blood cd34 positive selection kit ii
    NSG-Quad mice support human hematopoietic cell engraftment and multilineage immune cell development (A) Percentage of human CD45 + (hCD45 + ) cells of total CD45 + cells (mouse and human) in the blood at 8 weeks and 10–15 weeks post-engraftment with human-cord-blood-derived <t>CD34</t> + cells. (B) Human immune cell composition in the blood of NSG ( n = 33), NSG-Quad ( n = 34), and MISTRG-6 mice ( n = 32) 8 weeks post-engraftment and in the blood of NSG ( n = 29), NSG-Quad ( n = 25), and MISTRG-6 mice ( n = 16) 10–15 weeks post-engraftment. B cells (CD3 − CD56 − CD33 − CD20 + ), myeloid cells (CD3 − CD56 − CD20 − CD33 + ), NK cells (CD3 − CD56 + ), CD8 + T cells (CD3 + CD4 − CD8 + ), and CD4 + T cells (CD3 + CD8 − CD4 + ). (C) Percentage of human immune cell subsets in the blood 8 weeks post-engraftment (data from B). (D) Percentage of human immune cell subsets in the blood 10–15 weeks post-engraftment (data from B). Data are shown as mean ± SEM. p values were calculated using one-way or two-way ANOVA (A) with Tukey’s multiple comparison test. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.
    Easysep Human Cord Blood Cd34 Positive Selection Kit Ii, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/easysep+human+cord+blood+cd34+positive+selection+kit/easysep+human+t+cell+isolation+kit/pmc12152875-160-11-20
    Average 90 stars, based on 1 article reviews
    easysep human cord blood cd34 positive selection kit ii - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    easysep human cord blood cd34 positive selection kit  (STEMCELL Technologies Inc)
    90
    STEMCELL Technologies Inc easysep human cord blood cd34 positive selection kit
    NSG-Quad mice support human hematopoietic cell engraftment and multilineage immune cell development (A) Percentage of human CD45 + (hCD45 + ) cells of total CD45 + cells (mouse and human) in the blood at 8 weeks and 10–15 weeks post-engraftment with human-cord-blood-derived <t>CD34</t> + cells. (B) Human immune cell composition in the blood of NSG ( n = 33), NSG-Quad ( n = 34), and MISTRG-6 mice ( n = 32) 8 weeks post-engraftment and in the blood of NSG ( n = 29), NSG-Quad ( n = 25), and MISTRG-6 mice ( n = 16) 10–15 weeks post-engraftment. B cells (CD3 − CD56 − CD33 − CD20 + ), myeloid cells (CD3 − CD56 − CD20 − CD33 + ), NK cells (CD3 − CD56 + ), CD8 + T cells (CD3 + CD4 − CD8 + ), and CD4 + T cells (CD3 + CD8 − CD4 + ). (C) Percentage of human immune cell subsets in the blood 8 weeks post-engraftment (data from B). (D) Percentage of human immune cell subsets in the blood 10–15 weeks post-engraftment (data from B). Data are shown as mean ± SEM. p values were calculated using one-way or two-way ANOVA (A) with Tukey’s multiple comparison test. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.
    Easysep Human Cord Blood Cd34 Positive Selection Kit, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/easysep+human+cord+blood+cd34+positive+selection+kit/easysep+human+t+cell+isolation+kit/pm39318093-168-11-19
    Average 90 stars, based on 1 article reviews
    easysep human cord blood cd34 positive selection kit - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    easysep human cord blood cd34 positive selection stem cell isolation kit  (STEMCELL Technologies Inc)
    90
    STEMCELL Technologies Inc easysep human cord blood cd34 positive selection stem cell isolation kit
    NSG-Quad mice support human hematopoietic cell engraftment and multilineage immune cell development (A) Percentage of human CD45 + (hCD45 + ) cells of total CD45 + cells (mouse and human) in the blood at 8 weeks and 10–15 weeks post-engraftment with human-cord-blood-derived <t>CD34</t> + cells. (B) Human immune cell composition in the blood of NSG ( n = 33), NSG-Quad ( n = 34), and MISTRG-6 mice ( n = 32) 8 weeks post-engraftment and in the blood of NSG ( n = 29), NSG-Quad ( n = 25), and MISTRG-6 mice ( n = 16) 10–15 weeks post-engraftment. B cells (CD3 − CD56 − CD33 − CD20 + ), myeloid cells (CD3 − CD56 − CD20 − CD33 + ), NK cells (CD3 − CD56 + ), CD8 + T cells (CD3 + CD4 − CD8 + ), and CD4 + T cells (CD3 + CD8 − CD4 + ). (C) Percentage of human immune cell subsets in the blood 8 weeks post-engraftment (data from B). (D) Percentage of human immune cell subsets in the blood 10–15 weeks post-engraftment (data from B). Data are shown as mean ± SEM. p values were calculated using one-way or two-way ANOVA (A) with Tukey’s multiple comparison test. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.
    Easysep Human Cord Blood Cd34 Positive Selection Stem Cell Isolation Kit, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/easysep+human+cord+blood+cd34+positive+selection+kit/easysep+human+t+cell+isolation+kit/pm39108072-38-15-26
    Average 90 stars, based on 1 article reviews
    easysep human cord blood cd34 positive selection stem cell isolation kit - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    NSG-Quad mice support human hematopoietic cell engraftment and multilineage immune cell development (A) Percentage of human CD45 + (hCD45 + ) cells of total CD45 + cells (mouse and human) in the blood at 8 weeks and 10–15 weeks post-engraftment with human-cord-blood-derived CD34 + cells. (B) Human immune cell composition in the blood of NSG ( n = 33), NSG-Quad ( n = 34), and MISTRG-6 mice ( n = 32) 8 weeks post-engraftment and in the blood of NSG ( n = 29), NSG-Quad ( n = 25), and MISTRG-6 mice ( n = 16) 10–15 weeks post-engraftment. B cells (CD3 − CD56 − CD33 − CD20 + ), myeloid cells (CD3 − CD56 − CD20 − CD33 + ), NK cells (CD3 − CD56 + ), CD8 + T cells (CD3 + CD4 − CD8 + ), and CD4 + T cells (CD3 + CD8 − CD4 + ). (C) Percentage of human immune cell subsets in the blood 8 weeks post-engraftment (data from B). (D) Percentage of human immune cell subsets in the blood 10–15 weeks post-engraftment (data from B). Data are shown as mean ± SEM. p values were calculated using one-way or two-way ANOVA (A) with Tukey’s multiple comparison test. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.

    Journal: Molecular Therapy. Methods & Clinical Development

    Article Title: Comparison of NSG-Quad and MISTRG-6 humanized mice for modeling circulating and tumor-infiltrating human myeloid cells

    doi: 10.1016/j.omtm.2025.101487

    Figure Lengend Snippet: NSG-Quad mice support human hematopoietic cell engraftment and multilineage immune cell development (A) Percentage of human CD45 + (hCD45 + ) cells of total CD45 + cells (mouse and human) in the blood at 8 weeks and 10–15 weeks post-engraftment with human-cord-blood-derived CD34 + cells. (B) Human immune cell composition in the blood of NSG ( n = 33), NSG-Quad ( n = 34), and MISTRG-6 mice ( n = 32) 8 weeks post-engraftment and in the blood of NSG ( n = 29), NSG-Quad ( n = 25), and MISTRG-6 mice ( n = 16) 10–15 weeks post-engraftment. B cells (CD3 − CD56 − CD33 − CD20 + ), myeloid cells (CD3 − CD56 − CD20 − CD33 + ), NK cells (CD3 − CD56 + ), CD8 + T cells (CD3 + CD4 − CD8 + ), and CD4 + T cells (CD3 + CD8 − CD4 + ). (C) Percentage of human immune cell subsets in the blood 8 weeks post-engraftment (data from B). (D) Percentage of human immune cell subsets in the blood 10–15 weeks post-engraftment (data from B). Data are shown as mean ± SEM. p values were calculated using one-way or two-way ANOVA (A) with Tukey’s multiple comparison test. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.

    Article Snippet: Human CD34 + HSPCs were isolated from cord blood using an EasySep Human Cord Blood CD34 Positive Selection Kit II (StemCell Technologies, #17896).

    Techniques: Derivative Assay, Comparison

    NSG-Quad mice support the development of human myeloid cells (A) Percentage of human CD45 + (hCD45 + ) cells of total CD45 + cells (mouse and human) in the blood of NSG-Quad +/− mice (heterozygous M-CSF, n = 24) and NSG-Quad +/+ mice (homozygous M-CSF, n = 9) at 10–15 weeks post-engraftment with human-cord-blood-derived CD34 + cells. (B) Human immune cell composition in the blood of NSG-Quad +/− mice ( n = 24) and NSG-Quad +/+ mice ( n = 9) 10–15 weeks post-engraftment. (C) Percentage of human immune cell subsets in the blood of NSG-Quad +/− and NSG-Quad +/+ mice 10–15 weeks post-engraftment (data from B). (D) Percentage of human CD45 + (hCD45 + ) cells of total CD45 + cells (mouse and human) in the blood at 8 weeks and 10–15 weeks post-engraftment with human-cord-blood-derived CD34 + cells. (E) Human immune cell composition in the blood of NSGS ( n = 11) and NSG-Quad mice ( n = 25) 10–15 weeks post-engraftment. (F) Percentage of human immune cell subsets in the blood of NSGS and NSG-Quad mice 10–15 weeks post-engraftment (data from E). Data are shown as mean ± SEM. p values were calculated using two-tailed, unpaired Student’s t test (A), two-way ANOVA with Tukey’s multiple comparison test (D) and two-tailed, unpaired Mann-Whitney U test (C, F). ∗ p < 0.05, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.

    Journal: Molecular Therapy. Methods & Clinical Development

    Article Title: Comparison of NSG-Quad and MISTRG-6 humanized mice for modeling circulating and tumor-infiltrating human myeloid cells

    doi: 10.1016/j.omtm.2025.101487

    Figure Lengend Snippet: NSG-Quad mice support the development of human myeloid cells (A) Percentage of human CD45 + (hCD45 + ) cells of total CD45 + cells (mouse and human) in the blood of NSG-Quad +/− mice (heterozygous M-CSF, n = 24) and NSG-Quad +/+ mice (homozygous M-CSF, n = 9) at 10–15 weeks post-engraftment with human-cord-blood-derived CD34 + cells. (B) Human immune cell composition in the blood of NSG-Quad +/− mice ( n = 24) and NSG-Quad +/+ mice ( n = 9) 10–15 weeks post-engraftment. (C) Percentage of human immune cell subsets in the blood of NSG-Quad +/− and NSG-Quad +/+ mice 10–15 weeks post-engraftment (data from B). (D) Percentage of human CD45 + (hCD45 + ) cells of total CD45 + cells (mouse and human) in the blood at 8 weeks and 10–15 weeks post-engraftment with human-cord-blood-derived CD34 + cells. (E) Human immune cell composition in the blood of NSGS ( n = 11) and NSG-Quad mice ( n = 25) 10–15 weeks post-engraftment. (F) Percentage of human immune cell subsets in the blood of NSGS and NSG-Quad mice 10–15 weeks post-engraftment (data from E). Data are shown as mean ± SEM. p values were calculated using two-tailed, unpaired Student’s t test (A), two-way ANOVA with Tukey’s multiple comparison test (D) and two-tailed, unpaired Mann-Whitney U test (C, F). ∗ p < 0.05, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.

    Article Snippet: Human CD34 + HSPCs were isolated from cord blood using an EasySep Human Cord Blood CD34 Positive Selection Kit II (StemCell Technologies, #17896).

    Techniques: Derivative Assay, Two Tailed Test, Comparison, MANN-WHITNEY

    NSG-Quad mice promote the development of tumor-infiltrating human macrophages (A) Tumor growth curves in NSG ( n = 9), NSG-Quad ( n = 12), and MISTRG-6 mice ( n = 15) engrafted with SW480 CRC cells and in NSG ( n = 10), NSG-Quad ( n = 4), and MISTRG-6 mice ( n = 14) engrafted with HCT116 CRC cells. (B) Frequency of hCD45 + cells in the tumor of NSG, NSG-Quad, and MISTRG-6 humanized mice engrafted with SW480 or HCT116 CRC cells (10–15 weeks post-engraftment with human-cord-blood-derived CD34 + cells; end of experiment). (C) Human immune cell composition in the blood of NSG, NSG-Quad, and MISTRG-6 humanized mice engrafted with SW480 or HCT116 CRC cells (10–15 weeks post-engraftment with human-cord-blood-derived CD34 + cells; end of experiment; data from G). (D) Human immune cell composition in the tumor xenografts of NSG ( n = 9, SW480; n = 10, HCT116), NSG-Quad ( n = 10, SW480; n = 3, HCT116), and MISTRG-6 mice ( n = 15, SW480; n = 12, HCT116). (E) Representative IHC pictures show SW480 CRC-infiltrating human CD68 + macrophages in NSG, NSG-Quad, and MISTRG-6 humanized mice. Scale bar: 50 μm. (F) Frequency of human CD68 + macrophages in CRC xenografts of NSG ( n = 11), NSG-Quad ( n = 7), and MISTRG-6 mice ( n = 15) analyzed by IHC. (G) Frequency of CD86 + (M1-like) and CD163 + (M2-like) human CD14 + monocytes in SW480 and HCT116 CRC xenografts of NSG-Quad ( n = 13) and MISTRG-6 mice ( n = 17). (H) Composition of the human CD33 + CD66b − myeloid cell population based on the expression of CD14, CD16, and HLA-DR in SW480 CRC xenografts of NSG-Quad ( n = 8) and MISTRG-6 ( n = 3) mice. Data are shown as mean ± SEM. p values were calculated using one-way or two-way ANOVA (G) with Tukey’s multiple comparison test. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.

    Journal: Molecular Therapy. Methods & Clinical Development

    Article Title: Comparison of NSG-Quad and MISTRG-6 humanized mice for modeling circulating and tumor-infiltrating human myeloid cells

    doi: 10.1016/j.omtm.2025.101487

    Figure Lengend Snippet: NSG-Quad mice promote the development of tumor-infiltrating human macrophages (A) Tumor growth curves in NSG ( n = 9), NSG-Quad ( n = 12), and MISTRG-6 mice ( n = 15) engrafted with SW480 CRC cells and in NSG ( n = 10), NSG-Quad ( n = 4), and MISTRG-6 mice ( n = 14) engrafted with HCT116 CRC cells. (B) Frequency of hCD45 + cells in the tumor of NSG, NSG-Quad, and MISTRG-6 humanized mice engrafted with SW480 or HCT116 CRC cells (10–15 weeks post-engraftment with human-cord-blood-derived CD34 + cells; end of experiment). (C) Human immune cell composition in the blood of NSG, NSG-Quad, and MISTRG-6 humanized mice engrafted with SW480 or HCT116 CRC cells (10–15 weeks post-engraftment with human-cord-blood-derived CD34 + cells; end of experiment; data from G). (D) Human immune cell composition in the tumor xenografts of NSG ( n = 9, SW480; n = 10, HCT116), NSG-Quad ( n = 10, SW480; n = 3, HCT116), and MISTRG-6 mice ( n = 15, SW480; n = 12, HCT116). (E) Representative IHC pictures show SW480 CRC-infiltrating human CD68 + macrophages in NSG, NSG-Quad, and MISTRG-6 humanized mice. Scale bar: 50 μm. (F) Frequency of human CD68 + macrophages in CRC xenografts of NSG ( n = 11), NSG-Quad ( n = 7), and MISTRG-6 mice ( n = 15) analyzed by IHC. (G) Frequency of CD86 + (M1-like) and CD163 + (M2-like) human CD14 + monocytes in SW480 and HCT116 CRC xenografts of NSG-Quad ( n = 13) and MISTRG-6 mice ( n = 17). (H) Composition of the human CD33 + CD66b − myeloid cell population based on the expression of CD14, CD16, and HLA-DR in SW480 CRC xenografts of NSG-Quad ( n = 8) and MISTRG-6 ( n = 3) mice. Data are shown as mean ± SEM. p values were calculated using one-way or two-way ANOVA (G) with Tukey’s multiple comparison test. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.

    Article Snippet: Human CD34 + HSPCs were isolated from cord blood using an EasySep Human Cord Blood CD34 Positive Selection Kit II (StemCell Technologies, #17896).

    Techniques: Derivative Assay, Expressing, Comparison